The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind

A new specialty drug gets FDA approval. The manufacturer announces pricing. Patients and prescribers are ready to start therapy. And then the claim comes back unpaid, not because the drug is denied, but because the system does not yet have a clean way to bill for it.

This is the coding gap, and it hits nearly every new physician-administered specialty drug the same way. A permanent HCPCS J-code typically takes 6 to 12 months to arrive after approval, sometimes longer. In the meantime, the drug bills under a miscellaneous or unclassified code—commonly J3590—alongside the NDC number, an invoice, and a letter of medical necessity. Every one of those claims gets pulled for manual review. Processing slows, denials and pends climb, and centers front the cost of product that has already been administered while waiting weeks for clean payment.

Novartis's intrathecal Zolgensma, approved in 2025, did not receive its permanent J-code, J3405, until July 1, 2026.^1,2 That is roughly a year of miscellaneous-code billing for a product that already had a well-established IV predecessor. A genuinely novel therapy with no prior analog can expect the same timeline or longer.

The gap is not a paperwork inconvenience. It is a cash flow problem with clinical consequences. A center holding 6 figures of inventory for a rare disease therapy, waiting on a coding fix rather than a clinical decision, is a real and underdiscussed barrier to access, separate from prior authorization, separate from formulary placement, and almost invisible until a pharmacy team lives through it.

There are 3 places this shows up right now:

1. Ultra-rare, ultra-small populations. Several therapies now in development or recently approved target patient populations in the low hundreds nationally. The newest add-on therapy for spinal muscular atrophy (SMA), apitegromab (Isembyld; Scholar Rock), carries a label that requires the patient to already be on an SMN2-targeted therapy, such as nusinersen (Spinraza; Biogen) or risdiplam (Evrysdi; Genentech).³ That is not an edge case for this drug; it is the entire label. Existing prior authorization policies for SMA therapies have historically done the opposite, explicitly prohibiting concomitant use of more than one disease-modifying agent at a time. A drug whose own FDA label requires combination therapy now has to be layered onto payer policy built around the assumption that combination therapy should not happen. Rewriting that policy takes time the coding gap does not wait for.
2. Cold chain and ultra-rare metabolic disease. Therapies for conditions like propionic acidemia, affecting roughly 100 to 150 treated patients nationwide, face the coding gap on top of a genuinely difficult distribution problem.⁴ A frozen, patient-specific biologic dosed every 2 to 3 weeks needs validated cold chain handling and a narrow post-thaw stability window. Centers cannot hold meaningful inventory for a population this small, which means every dose is a logistics event, and every one of those logistics events is happening before a specific code exists to bill it cleanly.
3. Devices crossing into drug-adjacent territory. The coding gap is not limited to drugs. A newer kidney stone treatment technology, burst wave lithotripsy, fragments stones using a fundamentally different mechanism than conventional extracorporeal shock wave lithotripsy, yet shares the same patient population and clinical goal.⁵

The question payers now face is whether to crosswalk the new technology onto the existing procedural code or push it toward a Category III tracking code, the same kind of code used for several shockwave therapy applications that payers routinely treat as investigational regardless of the underlying evidence.^6,7 The decision shapes access just as much as any clinical trial result does, and it is happening committee by committee, payer by payer, without a uniform answer.

What Pharmacists in Benefit and Access Roles Can Actually Do

• Build the coding timeline into patient and prescriber expectations from day 1. A clear explanation that the first several months of therapy may involve manual claims review, not clinical denial, prevents a lot of unnecessary panic and appeals.
• Document everything a miscellaneous code claim needs before the first dose, not after the first denial. NDC, invoice, letter of medical necessity, and a clear escalation contact at the manufacturer's hub should be assembled in advance for any launch-phase product.
• Push manufacturers on hub support specifically for the coding period, not just financial assistance. A hub that proactively handles miscellaneous-code documentation and appeals during the pre-permanent-code window is doing real access work, and it is a fair question to ask a manufacturer representative directly.
• Flag combination-therapy label requirements to your P&T committee before launch, not after the first denied claim. If a new therapy's label requires background therapy that existing policy prohibits combining, that conflict is foreseeable and fixable in advance.

The coding gap will not close industry-wide anytime soon. HCPCS codes move on a quarterly cycle, and permanent code decisions follow their own administrative timeline regardless of how urgently a patient needs treatment. But the operational friction inside that gap is manageable, and the pharmacists and access teams who plan for it, rather than discover it midlaunch, are the ones actually closing the distance between FDA approval and a patient's first paid claim.

REFERENCES

1. Centers for Medicare and Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Determinations First Quarter, 2026 HCPCS Coding Cycle. Accessed October 1, 2026. https://www.cms.gov/files/document/2026-hcpcs-application-summary-quarter-1-2026-drugs-biologicals.pdf

2. Centers for Medicare and Medicaid Services. HCPCS code J3405 effective date, July 1, 2026. Accessed October 1, 2026. https://public.powerdms.com/PHPNI/documents/3760596

3. ISEMBYLD (apitegromab-mstn) prescribing information. Updated September 2026. Accessed October 1, 2026. https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf

4. Recordati Announces Strategic Collaboration With Moderna To Develop and Commercialize Worldwide mRNA 3927 for the Treatment of Propionic Acidemia. News release. FirstWord Pharma. January 30, 2026. Accessed October 1, 2026. https://firstwordpharma.com/story/7086553

5. Sonomotion Announces FDA Clearance for its Break Wave Lithotripsy Device for Treatment of Kidney Stones. January 21, 2026. Accessed October 1, 2026. https://www.prnewswire.com/news-releases/sonomotion-announces-fda-clearance-for-its-break-wave-lithotripsy-device-for-treatment-of-kidney-stones-302666229.html

6. Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications. United Healthcare. Accessed October 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/extracorporeal-shock-wave-therapy.pdf

7. Is Shockwave Therapy Covered by Insurance? A Reimbursement Guide for Providers. Softwave. Accessed October 1, 2026. https://softwavetrt.com/is-shockwave-therapy-covered-by-insurance/